Emil D. Kakkis M.D., Ph.D.
Net Worth
Last updated:
What is Emil D. Kakkis M.D., Ph.D. net worth?
The estimated net worth of Dr. Emil D. Kakkis M.D., Ph.D. is at least $85,647,923 as of 10 Dec 2024. He owns shares worth $65,651,789 as insider, has earned $5,696,134 from insider trading and has received compensation worth at least $14,300,000 in Ultragenyx Pharmaceutical Inc..
What is the salary of Emil D. Kakkis M.D., Ph.D.?
Dr. Emil D. Kakkis M.D., Ph.D. salary is $1,430,000 per year as Pres, Chief Executive Officer & Director in Ultragenyx Pharmaceutical Inc..
How old is Emil D. Kakkis M.D., Ph.D.?
Dr. Emil D. Kakkis M.D., Ph.D. is 65 years old, born in 1960.
What stocks does Emil D. Kakkis M.D., Ph.D. currently own?
As insider, Dr. Emil D. Kakkis M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | Pres, Chief Executive Officer & Director | 2,195,712 | $29.9 | $65,651,789 |
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Emil D. Kakkis M.D., Ph.D. insider trading
Ultragenyx Pharmaceutical Inc.
Dr. Emil D. Kakkis M.D., Ph.D. has made 23 insider trades between 2015-2024, according to the Form 4 filled with the SEC. Most recently he sold 8,273 units of RARE stock worth $413,650 on 10 Dec 2024.
The largest trade he's ever made was exercising 47,853 units of RARE stock on 19 Oct 2023. As of 10 Dec 2024 he still owns at least 2,195,712 units of RARE stock.
Ultragenyx Pharmaceutical key executives
Ultragenyx Pharmaceutical Inc. executives and other stock owners filed with the SEC:
- Dr. Camille L. Bedrosian M.D. (72) Chief Medical Officer & Executive Vice President
- Dr. Emil D. Kakkis M.D., Ph.D. (65) Pres, Chief Executive Officer & Director
- Mr. Erik Harris (55) Executive Vice President & Chief Commercial Officer
- Mr. John Richard Pinion II (59) Chief Quality Operations Officer & Executive Vice President of Translational Sciences
- Ms. Mardi C. Dier (61) Executive Vice President & Chief Financial Officer